Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab-Reference-Cited by-同舟云学术

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab

Published:2018-08-14 Issue:8 Volume:58 Page:1225-1235
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Ayer David W.¹,Skljarevski Vladimir¹,Ford Janet H.¹,Nyhuis Allen W.¹,Lipton Richard B.²,Aurora Sheena K.¹

Affiliation:

1. Eli Lilly and Company; Indianapolis IN USA

2. Departments of Neurology, Epidemiology and Population Health, and Psychiatry and Behavioral Science; Albert Einstein College of Medicine; Bronx NY USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/head.13383/fullpdf

Reference39 articles.

1. The International Classification of Headache Disorders, 3rd edition (beta version);Headache Classification Committee of the International Headache Society (IHS);Cephalalgia,2013

2. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy;Lipton;Neurology,2007

3. Disability and quality of life in headache: Where we are now and where we are heading;D'Amico;Neurol Sci,2013